View stunning SlideShares in full-screen with the new iOS app!Introducing SlideShare for AndroidExplore all your favorite topics in the SlideShare appGet the SlideShare app to Save for Later — even offline
View stunning SlideShares in full-screen with the new Android app!View stunning SlideShares in full-screen with the new iOS app!
2001-2013 Participated in the following studies as Principal Investigator
Novartis AGO. “An 8 week, multicenter, randomized, double blind, placebo and paroxetine study of the
efficacy, safety and tolerability of agomelatine 25 or 50 mg given once daily in the treatment of Major
Depressive Disorder (MDD) followed by a 28 week open label treatment with agomelatin 25 or 50 mg.”
Eisai ALF. “A 12 week Multi Center OPEN Label , Place study to evaluate the effectiveness and safety of
Donepezil (Aricept) in Mild to Severe Alzheimers Disease residing in Assisted Living Facility.”
A multicenter, double-blind, randomized, parallel group, active-controlled tolerability and safety study
of MK-3756 (SM-13496/Lurasidone) in clinically stable schizophrenic outpatients (Merck: Protocol 021-
“A randomized, double-blind, placebo-controlled and olanzapine-referenced,
parallel-group efficacy and safety study of two fixed doses of bifeprunox in the treatment of
schizophrenia.” (Solvay/ Protocol S1543003/004/005)
“A six-week, double-blind, multicenter, placebo-controlled study evaluating the efficacy and safety of
flexible doses of oral ziprasidone in outpatients with bipolar I depression.” (Pfizer/ Protocol A1281139)
“A randomized, double-blind, placebo-controlled, efficacy, safety, and tolerability
study of bifeprunox in the treatment of elderly subjects with psychosis and behavioral disturbances
associated with dementia of the Alzheimer’s Type.” (Solvay /Protocol S1543016).
“Phase III Multicenter, randomized, double-blind placebo-controlled study of the
effect of daily treatment with MPC-7869 on measures of cognition, activities of daily living, and global
function in subjects with mild dementia of the Alzheimer’s type.” (Myriad / Protocol MPC-7869-04-
“A Multicenter, randomized, double-blind, parallel-group, fixed-dose study of the effect on weight of
bifeprenox versus olanzapine in the treatment of outpatients with schizophrenia.”(Wyeth/Protocol
A Multicenter, randomized, double-blind, parallel-group, fixed-dose study of the effect on weight of
bifeprenox versus risperidone in the treatment of outpatients with schizophrenia.”(Wyeth/Protocol
An open-label extension study to evaluate the long-term safety and
Tolerability OfBifeprunox in the treatment of outpatients with
Schizophrenia (Wyeth 3168A1-312, 314)
A Randomized, Multicenter, Double-blind, Parallel Group Study to
Compare the Effects of Bifeprunox and Quetiapine on
Weight Changes in Stable Schizophrenia Patients. (Solvay/ Protocol
A multi-center, openl label, parallel group, randomized, flexible dose
study to evaluate the safety and tolerability of switching from existing
atypical antipsychotics to bifeprunox in subjects with schizophrenia or
schizoaffective disorder ( Solvay/Protocol S154.3.020-Subinvestigator)
A multicenter, open-label, flexible-dose, parallel-group evaluation of the
cataractogenic potential of quetiapinefumarate (SEROQUEL TM) and
risperidone (RISPERDAL TM) in the long-term treatment of patients with
schizophrenia or schizoaffective disorder (Protocol 5077IL/0089/
A Four-Week Double Blind Multi-Center Study Comparing the Efficacy
and Safety of the Ziprasidone to Aripiprazole in Subjects With
Schizophrenia or Schizoaffective Disorder Needing Inpatient Care.
(Sub investigator/Rater). Supported by Pfizer.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
With An Open-Label Extension Evaluating Extended Release OROS®
Paliperidone in the Prevention of Recurrence in Subjects With
Schizophrenia: Protocol: R076477-SCH-301
Extension Protocol: R076477-SCH-701. (Sub-investigator/Rater).
Supported by Johnson & Johnson.
Zodiac Study. An International, Multicenter Large Simple Trial (LST) to
Compare the Cardiovascular Safety of Ziprasidone and Olanzapine.
(Principal Investigator).Supported by Pfizer.
Janssen RIS-OUT-173.“A prospective 2 year observational study of patients with schizophrenia, who
initiate treatment with RISPERDAL CONSTA.”
Use of Depakote on agitated dementias. (Principal Investigator).
Supported by Abbot.
Use of Reminyl in Lewy Body Dementia.(Principal Investigator).
Supported by Jenssen.
Use of Aricept in dementia of Alzheimer type.(Coordinator during
A 48-Week, Multicenter, Randomized, Double-blind, Parallel-Group
Evaluation of the Comparative Efficacy, Safety, and Tolerability
Of Exelon 10 and 15 cm2 Patch in Patients with Alzheimer’s
Disease Showing Cognitive Decline during an Initial Open-Label
TreatmentPhase (Protocol No. CENA713D2340/Novartis).
A Randomized, Placebo-Controlled, Double-blind, Parallel Group
Phase II b Study of AZD 340 in the Treatment of Cognitive Deficits
In Patients with Schizophrenia (Protocol No D3690C00011/AztraZeneca)
DSP Schizophrenia LTSS “Long-Term Safety, Tolerability, and Effectiveness of Lurasidone in Subjects with
Schizophrenia or Schizoaffective Disorder: A Randomized, Active Comparator-Controlled Trial” Protocol
DSP Alzheimer’s study “A Phase II, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-
Ranging Study Assessing the Efficacy and Safety of AC-3933 Tablets Twice Daily in Adults with Mild to
Moderate Alzheimer’s Disease”
Sanofi Aventis "A 24 Week, Multicenter, Double-Blind, Randomized, Parallel- Group, Dose Ranging
Study of the Efficacy and Safety of oral doses of AVE 1625 5, 10, and 30 mg and placebo on top of an
established treatment regimen of either olanzapine, risperidone/paliperidone,quetiapine or
aripiprazolemonotherapy in the treatment of Cognitive Impairment in Schizophrenia"
A52-week,Multicenter,Open-labelStudyto Evaluate the Effectiveness of Aripiprazole
Intramuscular Depot as Maintenance Treatment in Patients with Schizophrenia “ASPIRE OPEN-LABEL”
(Aripiprazole Intramuscular Depot Program in Schizophrenia)
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-
Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 3 Doses of LuAA21004 in Acute
Treatment of Adults with Generalized Anxiety Disorder. (Takeda Global Research)